Page 143 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 143
PET improves DLBCL response predictors
References
1. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817– 1826.
2. Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial. Lancet Oncol. 2013;14:525–533.
3. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35:544–551.
4. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
5. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:2373–2380.
6. Poeschel V, Held G, Ziepert M, et al. FLYER Trial Investigators; German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non- inferiority trial. Lancet. 2020;394:2271–2281.
7. Mikhaeel NG, Smith D, Dunn JT, et al. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur J Nucl Med Mol Imaging. 2016;43:1209–1219.
8. Schmitz C, Hüttmann A, Müller SP, et al. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial. Eur J Cancer. 2020;124:25–36.
9. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058.
10. Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. Groupe d’étude des lymphomes de l’adulte (GELA). SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37–43.
11. Dührsen U, Müller S, Hertenstein B, et al. PETAL Trial Investigators. Positron emission tomography- guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018;36:2024–2034.
12. Lugtenburg PJ, de Nully Brown P, van der Holt B, et al. Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase 3 trial of the HOVON and the Nordic Lymphoma Group (HOVON-84). J Clin Oncol. 2020;38:3377–3387.
13. Burggraaff CN, Cornelisse AC, Hoekstra OS, et al. HOVON Imaging Working Group. Interobserver agreement of interim and end-of-treatment (18)F-FDG PET/CT in diffuse large B-cell lymphoma (DLBCL): impact on clinical practice and trials. J Nucl Med. 2018;59:1831–1836.
14. Boellaard R. Quantitative oncology molecular analysis suite: ACCURATE [abstract]. J Nucl Med. 2018;59(suppl.1):1753.
15. Burggraaff CN, Rahman F, Kaßner I, et al. PETRA Consortium. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol Imaging Biol. 2020;22:1102–1110.
16. Barrington SF, Zwezerijnen BGJC, de Vet HCW, et al. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method Is most successful? A study on behalf of the PETRA consortium. J Nucl Med. 2021;62:332-337.
17. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068.
141
6a
